Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint

Cancer Treatment Reviews

Volumn 37, Issue 7, 2011, Pages 495-504

  Hurvitz, Sara A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Metastatic breast cancer; Overall survival; Progression free survival; Treatment options

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERIBULIN; FLUOROURACIL; GEMCITABINE; INIPARIB; IXABEPILONE; LAPATINIB; NAVELBINE; PACLITAXEL; PLACEBO; TRASTUZUMAB;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG FORMULATION; FEMALE; FOLLOW UP; GOLD STANDARD; HUMAN; METASTASIS; METHODOLOGY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SALVAGE THERAPY; SAMPLE SIZE;

BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; SURVIVAL RATE;

EID: 79959288115     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.01.002     Document Type: Review

References (48)

1. Food and Drug Administration. Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), May 2007.
2. Di Leo A., Bleiberg H., Buyse M. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 2003, 21(10):2045-2047.
3. Sledge G.W., Neuberg D., Bernardo P., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003, 21:588-592.
4. O'Shaughnessy J., Osborne C., Pippen J., et al. Final efficacy and safety results of a randomized phase II study of the PARP inhibitor iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple negative breast cancer (TNBC). Ann Oncol 2010, 21(s8):viii5. [abstr. LBA11].
5. Fleming T.R., Rothmann M.D., Lu H.L. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009, 27(17):2874-2880.
6. Saad E.D., Katz A., Hoff P.M., Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010, 21(1):7-12.
7. Mckee A.E., Farrell A.T., Pazdur R., Woodcock J. The role of the US food and drug administration review process: clinical trial endpoints in oncology. The Oncologist 2010, 15(s10):13-18.
8. Jones S.E., Erban J., Overmoyer B., Budd G.T., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005, 23(24):5542-5551.
9. Bontenbal M., Creemers G.J., Braun H.J., et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005, 23(28):7081-7088.
10. Jassem J., Pienkowski T., Pluzanska A., et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001, 19(6):1707-1715.
11. Jassem J., Pienkowski T., Pluzanska A., et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-Line therapy for women with advanced breast cancer: long-term analysis of the previously published trial. Onkologie 2009, 32(8-9):468-472.
12. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20(12):2812-2823.
13. Albain K.S., Nag S.M., Calderillo-Ruiz G., et al. Gemcitabine plus Paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008, 26(24):3950-3957.
14. Peto R. For the Early Breast Cancer Trialists' Collaborative Group University of Oxford. The worldwide overview: new results for systemic adjuvant therapies. Breast Cancer Res Treat 2007, 106(Suppl. 1). [abstr. P-1, plenary lecture].
15. Nabholtz J.M., Falkson C., Campos D., et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003, 21(6):968-975.
16. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23(31):7794-7803.
17. Sparano J.A., Makhson A.N., Semiglazov V.F., et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol 2009, 27(27):4522-4529.
18. Martin M., Ruiz A., Munoz M., et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007, 8(3):219-225.
19. Thomas E.S., Gomez H.L., Li R.K., et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007, 25(33):5210-5217.
20. Hortobagyi G.N., Gomez H.L., Li R.K., et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2010, 122:409-418.
21. Sparano J.A., Vrdoljak E., Rixe O., et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010, 28(20):3256-3263.
22. Twelves C., Loesch D., Blum J.L., et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline, a taxane. J Clin Oncol 2010, 28:18s. [abstr CRA1004^].
23. Schneider B.P., Miller K.D. Angiogenesis of breast cancer. J Clin Oncol 2005, 23(8):1782-1790.
24. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23(4):792-799.
25. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26):2666-2676.
26. O'Shaughnessy J., Miles D., Grey R.J., et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010, 28(15s):115s. [abstr. 1005].
27. Miles D.W., Chan A., Romieu G., et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008, 26(15S):43s. [abstr. LBA1011^].
28. Miles D.W., Chan A., Romieu G., et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). Cancer Res 2009, 69(24 Suppl. 3). [abstr. 41].
29. Robert N.J., Dieras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009, 27(15S):42s. [abstr. 1005].
30. Brufsky A., Bondarenko I.N., Smirnov V., et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 2009, 69(24 Suppl. 3):345. [abstr. 42].
31. Brufsky A., Rivera R.R., Hurvitz S.A., et al. Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2010, 28(15S):119s. [abstr. 1021].
32. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
33. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23(19):4265-4274.
34. Von Minckwitz G., Zielinski C., Maarteense E., et al. Capecitabine vs. capecitabine+trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment - the TBP phase III study (GBG 26/BIG 3-05). Ann Oncol 2008, 19(Suppl. 8):viii63. [abstr. 1330].
35. Cameron D., Casey M., Press M., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112(3):533-543.
36. O'Shaughnessy J., Blackwell K.L., Burstein H., et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008, 26(15S):44s. [abstr. 1015].
37. Blackwell K.L., Burstein H.J., Sledge G.W., et al. Updated survival analysis of a randomized study of Lapatinib alone or in combination with Trastuzumab in women with HER2-positive metastatic breast cancer progressing on Trastuzumab therapy. Cancer Res 2009, 69(24 Suppl. 3). [abstr. 61].
38. Schoppmann S.F., Tamandl D., Roberts L., et al. HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. Ann Oncol 2010, 21(5):955-960.
39. Konecny G.E., Meng Y.G., Untch M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004, 10(5):1706-1716.
40. Pegram M.D., Yeon C., Ku N.C., et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 2004, 88(Suppl. 1):S124. [abstr. 3039].
41. Eccles S.A. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001, 6(4):393-406.
42. Gaymes T.J., Shall S., MacPherson L.J., et al. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica 2009, 94(5):638-646.
43. Comen E.A., Robson M. Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology (Williston Park) 2010, 24(1):55-62.
44. Comen E.A., Robson M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J 2010, 16(1):48-52.
45. Saad E.D., Katz A., Machado K.K., Buyse M. Post-progression survival (PPS) and overall survival (OS) according to treatment type in contemporary phase III trials in advanced breast cancer (ABC). Cancer Res 2009, 69(24 Suppl. 3). [abstr. 5116].
46. Burzykowski T., Buyse M., Piccart-Gebhart M.J., et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008, 26(12):1987-1992.
47. Sherrill B., Amonkar M., Wu Y., et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 2008, 99(10):1572-1578.
48. Johnson K.R., Ringland C., Stokes B.J., et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006, 7:741-746.